How to buy Imugene (IMU) shares in Australia
Learn how to easily invest in Imugene shares.
How to buy shares in Imugene
- Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the ASX. Our table can help you choose.
- Open and fund your brokerage account. Complete an application with your personal and financial details, such as your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
- Search for Imugene . Find the share by name or ticker symbol: IMU. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Imugene reaches your desired price. Look into dollar-cost averaging to spread out your risk, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
- Check on your investment. Congratulations, you own a part of Imugene . Optimise your portfolio by tracking how your stock and the business performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that affect your stock.
Imugene stock price (ASX:IMU)Use our graph to track the performance of IMU stocks over time.
Imugene shares at a glance
|52-week range||$0.039 - $0.2|
|50-day moving average||$0.0597|
|200-day moving average||$0.0951|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-0.01|
Compare share trading platforms
Is it a good time to buy Imugene stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Imugene price performance over time
|1 week (2023-11-21)||10.53%|
|1 month (2023-10-27)||156.10%|
|3 months (2023-08-29)||66.67%|
|6 months (2023-05-29)||-4.55%|
|1 year (2022-11-29)||-41.67%|
|2 years (2021-11-29)||-79.41%|
|3 years (2020-11-27)||5.00%|
|5 years (2018-11-29)||356.52%|
|Revenue TTM||$11.8 million|
|Gross profit TTM||$11.8 million|
|Return on assets TTM||-14.33%|
|Return on equity TTM||-23.1%|
|Market capitalisation||$601.9 million|
TTM: trailing 12 months
Imugene share dividends
We're not expecting Imugene to pay a dividend over the next 12 months.
Have Imugene 's shares ever split?
Imugene 's shares were split on a 1:7.5 basis on 12 November 2002. So if you had owned 7.5 shares the day before the split, the next day you would own 1 share. This wouldn't directly have changed the overall worth of your Imugene shares – just the quantity. However, indirectly, the new 650% higher share price could have impacted the market appetite for Imugene shares which in turn could have impacted Imugene 's share price.
Imugene share price volatility
Over the last 12 months, Imugene 's shares have ranged in value from as little as $0.039 up to $0.2. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Imugene 's is 2.543. This would suggest that Imugene 's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in phase 2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling and is in phase I trial; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a collaboration with Arovella Therapeutics Ltd to test the integration of Arovella's CAR19- iNKT cell therapy with the onCARlytics platform, as well as a research collaboration with RenovoRx, Inc. to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.
Stocks similar to Imugene
Imugene in the news
Frequently asked questions
More guides on Finder
How to buy OpenAI stock in Australia
Looking to jump on the AI bandwagon? Here's how you can invest in ChatGPT and its parent company OpenAI from Australia.
Best performing stocks on the ASX in 2023 (Updated weekly)
Looking for the best performing stocks in Australia? We update this list weekly.
Cryptocurrency ETFs explained: A simple guide for investors (2023)
If you’re looking for ways to gain exposure to Bitcoin and other digital currencies, cryptocurrency ETFs could be worth exploring. Find out what crypto ETFs are and how they work in this introductory guide.
How to buy Gol Linhas Aereas Inteligentes SA ADR (GOL) shares in Australia
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
How to buy Microsoft (MSFT) shares in Australia
Steps to owning and managing Microsoft shares from in Australia.
A beginner’s guide to Lego investing
Looking for alternative investments? With a ROI of up to 3,593% lego may be worth considering. Read on to find out which lego sets are worth the investment.
The cheapest stock brokers in Australia (Nov 2023)
Find cheap stock brokerage in Australia when buying and selling shares on the ASX and other international exchanges.
What is the money market?
Learn about the money market and everyday consumer money market products.
Is investing in crowdfunding a safe investment?
Equity crowdfunding offers a unique opportunity for investors and for Australian startups, but Australia’s regulatory framework surrounding crowdfunding still lags behind the rest of the world.
The best trading platforms in Australia for 2023
Follow these tips to find the best share trading platform for you.
Ask an Expert